Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in chinese valve replacement patients
Open Access
- 27 September 2012
- journal article
- Published by Springer Science and Business Media LLC in Journal of Cardiothoracic Surgery
- Vol. 7 (1), 97
- https://doi.org/10.1186/1749-8090-7-97
Abstract
Background: Individuals with implanted mechanical valve prostheses require lifelong anticoagulation therapy with warfarin. The narrow therapeutic index of warfarin makes it difficult to dose and maintain proper anticoagulation. A number of single nucleotide polymorphisms (SNPs) affecting vitamin K or warfarin metabolism have been shown to affect warfarin dosing. Our aim was to study the effect of the CYP4F2 rs2108622-1347 (C > T) variant on warfarin dosing in Chinese patients.Methods: We studied 352 patients after heart valve replacement surgery. Warfarin dosing for patients was adjusted to achieve 1.8 ≤ INR ≤ 2.5. We determined the presence of SNPs in CYP4F2 in these patients and investigated their association with warfarin dosing.Results: We found the frequency of the CYP4F2 rs2108622 C allele was 79.5% and T-allele frequency was 20.5%. The warfarin dose requirement for CC individuals was significantly lower than that for CT or TT individuals (P < 0.05). TT-homozygous individuals required a 0.56 mg/day higher dose of warfarin than their CC counterparts.Conclusions: This study demonstrates that CYP4F2 rs2108622 significantly affects the warfarin dose requirement to achieve adequate anticoagulant activity in Chinese individuals. Genotyping of this SNP may allow clinicians to determine the initiation dose for patients following valve-replacement surgery in China.Keywords
This publication has 21 references indexed in Scilit:
- Genetic Variation of VKORC1 and CYP4F2 Genes Related to Warfarin Maintenance Dose in Patients with Myocardial InfarctionJournal of Biomedicine and Biotechnology, 2010
- CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacementBritish Journal of Clinical Pharmacology, 2010
- Pharmacogenetics of acenocoumarol in patients with extreme dose requirementsJournal of Thrombosis and Haemostasis, 2010
- Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement— A systematic review and meta analysisThrombosis Research, 2010
- A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin DosePLoS Genetics, 2009
- CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M VariantMolecular Pharmacology, 2009
- Current developments and future prospects for heart valve replacement therapyJournal of Biomedical Materials Research Part B: Applied Biomaterials, 2008
- CYP4F2 genetic variant alters required warfarin dosePublished by American Society of Hematology ,2008
- The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimenBlood, 2005
- Expression and Molecular Cloning of Human Liver Leukotriene B4 omega-Hydroxylase (CYP4F2) GeneDNA and Cell Biology, 1999